Stocks · News reference
SCYNEXIS reported positive Phase 1 trial results for its intravenous antifungal candidate SCY-247 and secured up to $214 million in non-dilutive funding from BARDA to support its development.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
SCYNEXIS, Inc. announced that its senior leadership team will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference in Boston, scheduled for November 9-11, 2026.
SCYNEXIS announced it will present information regarding its pipeline candidate SCY-247 at the upcoming IDWeek conference.
SCYNEXIS announced positive Phase 1 results for SCY-247, an intravenous antifungal candidate for invasive fungal diseases. The drug was well-tolerated with no serious adverse events, and doses of 50 mg or higher achieved target exposures identified in preclinical models. The company received a BARDA contract worth up to $214 million and plans to initiate Phase 2 studies in 2027 for both oral and IV formulations.